News Summary: Pfizer rheumatoid arthritis drug

Associated Press

APPROVAL: Pfizer Inc. says the Food and Drug Administration approved its rheumatoid arthritis drug Xeljanz, a twice-per-day pill.

WHO IT'S FOR: Xeljanz is designed to slow the progression of moderate to severe rheumatoid arthritis. It is approved for patients who either cannot take methotrexate, a standard treatment for the disease, or haven't been helped by it. Xeljanz interferes with enzymes that contribute to tissue inflammation.

THE BIG PICTURE: Rheumatoid arthritis is a major area of research for drug companies because it is a chronic condition, meaning patients will likely take the drugs regularly for a long time.

Sorry you didn't like this comment. Please provide a reason below.

Are you sure?
Rating failed. Try again.
Request failed. Try again.
We will promote constructive and witty comments to the top, so everyone sees them!
Sorry, we can’t load comments right now. Try again.

    Recommended for You